Perspective: Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies

Tariq I. Mughal, Naveen Pemmaraju, Rafael Bejar, Robert P. Gale, Prithviraj Bose, Jean Jacques Kiladjian, Josef Prchal, Daniel Royston, Daniel Pollyea, Peter Valent, Tim H. Brümmendorf, Tomasz Skorski, Mrinal Patnaik, Valeria Santini, Pierre Fenaux, Nicole Kucine, Srdan Verstovsek, Ruben Anthony Mesa, Tiziano Barbui, Guiseppe SaglioRichard A. Van Etten

Research output: Contribution to journalReview articlepeer-review

Abstract

Despite much of the past 2 years being engulfed by the devastating consequences of the SAR-CoV-2 pandemic, significant progress, even breathtaking, occurred in the field of chronic myeloid malignancies. Some of this was show-cased at the 15th Post-American Society of Hematology (ASH) and the 25th John Goldman workshops on myeloproliferative neoplasms (MPN) held on 9th-10th December 2020 and 7th-10th October 2021, respectively. The inaugural Post-ASH MPN workshop was set out in 2006 by John Goldman (deceased) and Tariq Mughal to answer emerging translational hematology and therapeutics of patients with these malignancies. Rather than present a resume of the discussions, this perspective focuses on some of the pivotal translational hematology and therapeutic insights in these diseases.

Original languageEnglish (US)
JournalHematological Oncology
DOIs
StateAccepted/In press - 2022

Keywords

  • chronic myeloid leukemia
  • clinical
  • Myelofibrosis
  • systemic mastocytosis
  • thrombosis
  • translational

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Perspective: Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies'. Together they form a unique fingerprint.

Cite this